
Regeneron COVID-19 antibody cocktail helps prevent symptomatic disease in study
Fox News
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday.
The currently authorized dosage is 1,200 mg of casirivimab and 1,200 mg of imdevimab administered together as a single infusion within 10 days of symptom onset. The results announced Monday drew from a Phase 3 study involving 204 individuals who were randomly assigned to receive the drug via 1,200 mg injection or placebo.More Related News